BENGALURU, India, December 1, 2023 /PRNewswire/ — Biocon Biologics Ltd. (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the integration of Viatris’ biosimilar businesses in 31 European countries has been successfully completed.
Following the acquisition of almost all of the Viatris’ global biosimilars business in November 2022and related integration of more than 70 emerging countries July 2023 And North America In September 2023the complete transition of Viatris’ biosimilar activities to Biocon Biologics Ltd in Europe represents another important milestone as a global leader in biosimilars.
In Europe, Biocon Biologics’ portfolio includes 7 biosimilars: Insulin Aspart and Insulin Glargine, Bevacizumab, Pegfilgrastim, Trastuzumab, Adalimumab and Etanercept. Globally, Biocon Biologics has a strong pipeline of 20 assets across diabetes, oncology, immunology, ophthalmology and bone health. Serving more than 5.7 million patients annually, the company is committed to providing access to high-quality therapies and solutions to patients, health systems and governments around the world.
Shreehas Tambe, CEO & Managing Director, Biocon Biologics Ltdsaid: “The integration of Viatris’ biosimilar activity into Europe ahead of schedule marks another important milestone for Biocon Biologics in our journey as a global biosimilar leader. We are pleased to expand access to life-saving treatments for patients around the world. Europe. Our unique, fully integrated capabilities and robust portfolio of 20 products will enable us to better meet patient needs and be a trusted partner for healthcare organizations.“
Joseph BelcikSales Manager Europe and JANZ, Biocon Biologics Ltdsaid: “We are extremely pleased to have reached this historic moment and are proud to be leading the way in the advancement of biosimilars. As we continue to drive innovation and invest in the future, our mission is focused solely on the development, manufacturing, distribution and commercialization of biosimilars in Europe And in the world.“
Following the acquisition of Viatris, Biocon Biologics and its partners will market biosimilar products in the following countries: Albania, Austria, Belgium, Bosnia, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Malta, The Netherlands, Norway, Poland, Portugal, RomaniaSerbia, Slovakia, Slovenia, Spain, Sweden, Swissand the United Kingdom.
Note regarding biosimilars:
Based on the IQVIA white paper “The impact of biosimilar competition EuropeIQVIA (2022)”, from 2022, cumulative savings at list prices due to the impact of competition from biosimilars in Europe reached more than 30 billion euros. Additionally, since the launch of biosimilars, they have provided nearly 4.5 billion days of treatment to European patients.
Source:
1-Tthe impact of competition from biosimilars in EuropeIQVIA (2022)
December 2022. https://www.iqvia.com/-/media/iqvia/pdfs/library/white-papers/the-impact-of-biosimilar-competition-in-europe-2022.pdf
About Biocon Biologics Limited:
Biocon Biologics Ltd., a subsidiary of Biocon Ltd., is a unique, fully integrated global biosimilars company committed to transforming healthcare and transforming lives by enabling affordable access to high-quality biosimilars for millions of patients around the world . It leverages cutting-edge science, innovative technology platforms, global manufacturing capabilities and world-class quality systems to reduce the costs of biologic therapies while improving healthcare outcomes.
BBL has acquired almost all of the global biosimilars business of its long-time partner Viatris, marking a historic step in its value creation journey. Biocon Biologics has commercialized eight biosimilars in key emerging and advanced markets such as the United States, Europe, Australia, CanadaAnd Japan.
The company has a portfolio of 20 biosimilar assets in the areas of diabetology, oncology, immunology, ophthalmology and other non-communicable diseases. She has many “firsts” to her credit in the biosimilar industry. As part of its environmental, social and governance (ESG) commitment, BBL advances the health of patients, people and the planet to achieve the key United Nations Sustainable Development Goals (SDGs). Website: www.bioconbiologics.com; Follow us on LinkedIn: Biocon Organic products ; Twitter: @BioconBiologics for company updates.
Biocon Limited, listed on the stock exchange in 2004 (BSE Code: 532523, NSE ID: BIOCON, ISIN ID: INE376G01013) is an innovation-driven, global biopharmaceutical company committed to improving affordable access to complex therapies for chronic diseases such as diabetes, cancer and autoimmune diseases. She has developed and commercialized novel biologics, biosimilars and complex small molecule APIs in India and several key global markets as well as generic formulations in the United States, Europe and major emerging markets. It also has a portfolio of promising new immunotherapy assets under development. Website: www.biocon.com; Follow us on Linked In: Biocon Limited; Twitter: @bioconlimited for company updates.
Forward-looking statements: Biocon
This press release may include statements of future expectations and other forward-looking statements based on management’s current expectations and beliefs regarding future developments and their potential effects on Biocon and its subsidiaries/associates. These forward-looking statements involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from our expectations include, among others: general economic and business conditions in India and overseas, our ability to successfully implement our strategy, research and development efforts, growth and expansion plans and technological changes, changes in the value of the rupee and other changes monetary conditions, changes in Indian and international interest rates, changes in laws and regulations that apply to the Indian and global biotechnology and pharmaceutical industries, increased competition and conditions for the Indian biotechnology and pharmaceutical industries and world, changes in political conditions in India and changes in exchange control regulations in India. Neither Biocon, our directors, nor any of our subsidiaries/associates assume any obligation to update any particular forward-looking statement contained in this release.
SOURCE Biocon Biologics Ltd.
